Abstract
A randomized trial was designed in order to compare the efficacy and feasibility of ProMECE-CytaBOM (P-C) and MACOP-B (M-B) in patients with advanced, aggressive non Hodgkin's lymphoma (NHL). P-C and M-B were chosen due to their association with a very high complete remission rate when compared to other published protocols. The study was conducted on 210 patients with intermediate or high-grade NHL in stage I bulky, or stages II-IV, randomized to receive either 6 courses of P-C delivered every 28 days (106 patients), or 12 weeks of M-B chemotherapy (104 patients). In both regimens doxorubicin was replaced by a 20% higher dose of epidoxorubicin (i.e. 30 mg/m2 of the analog). At the end of induction therapy patients could receive additional radiotherapy to residual masses or to sites of previous bulky disease. The two groups of patients were compared for response rates, number and severity of therapy related side effects, overall survival, disease-free survival, and time to treatment failure. Sixty-five patients (62%) treated with P-C and 69 patients (67%) treated with M-B achieved a complete remission, with no significant differences between the two treatment arms (P = 0.13). The overall objective response rate (complete + parti...Continue Reading
References
Oct 1, 1976·Annals of Internal Medicine·P S ScheinR C Young
Jan 1, 1977·British Journal of Cancer·R PetoP G Smith
Nov 5, 1992·The New England Journal of Medicine·L I GordonA Gottlieb
Jan 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M SchneiderB D Clarkson
Dec 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T P MillerR I Fisher
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M MeyerM D Goodyear
Sep 15, 1990·Cancer·R EpelbaumY Cohen
Apr 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M H Cohen
Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D B BoydD McDermott
Oct 1, 1989·European Journal of Cancer & Clinical Oncology·U VitoloG Luxi
May 1, 1985·Annals of Internal Medicine·P Klimo, J M Connors
Nov 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Hryniuk, H Bush
Mar 1, 1983·Annals of Internal Medicine·R I FisherR C Young
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I A CooperF C Firkin
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Dec 9, 1993·The New England Journal of Medicine·R M MeyerL E Shepherd
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Apr 8, 1993·The New England Journal of Medicine·J O Armitage
Citations
Nov 19, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BariM C Cox
Jan 27, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L LeeM Crump
Jan 1, 1997·Leukemia & Lymphoma·F CaraccioloM Petrini
Dec 30, 2009·Leukemia & Lymphoma·Donato ManninaMassimo Federico
Feb 3, 2006·European Journal of Haematology·Massimo FedericoMaura Brugiatelli
Sep 16, 2003·Cancer·Li-Yuan BaiPo-Min Chen
Dec 7, 2017·Oncotarget·Pengcheng CaiJiawei Xu
Nov 1, 1996·European Journal of Haematology·E MontserratJ Estapé
Jul 1, 1996·European Journal of Haematology·A VecchiS Sacchi
Feb 1, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P G GobbiUNKNOWN Gruppo Italiano Studio Linfomi